昆藥集團(600422.SH):貝克銷售獲磺達肝癸鈉指定區域獨家推廣權益
格隆匯3月4日丨昆藥集團(600422.SH)公佈,鑑於兆科藥業(合肥)有限公司(以下簡稱“兆科藥業”或“甲方”)研發的磺達肝癸鈉注射液於近期獲得國家藥品監督管理局簽發的生產及上市批文,根據公司全資孫公司昆明貝克諾頓藥品銷售有限公司(以下簡稱“貝克銷售”或“乙方”)與兆科藥業簽訂的《產品銷售服務協議》等協議約定,貝克銷售向兆科藥業支付首筆市場權利金後,兆科藥業將磺達肝癸鈉注射液在中國大陸(即中華人民共和國除香港特別行政區、澳門特別行政區及台灣地區以外的區域)指定區域(以下簡稱“指定區域”)的獨家推廣權益授予貝克銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.